Navigation Links
Pearl Therapeutics' Bronchodilator Combination PT003 Provides Superior Inspiratory Capacity Compared to Spiriva®
Date:9/26/2011

REDWOOD CITY, Calif., Sept. 26, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. presented additional positive results from its  Phase 2b study (NCT01085045) demonstrating that the dual bronchodilator combination product, PT003 (GFF MDI) provides superior inspiratory capacity (IC) compared to Spiriva® HandiHaler® (tiotropium bromide inhalation powder). IC is a lung function measurement that has been shown to be predictive of improvement in exercise performance in patients with COPD. PT003 is a proprietary fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist (LABA) delivered via a pressurized hydrofluoroalkane metered dose inhaler (HFA MDI). In a separate analysis, the Company also confirmed the comparability of their monotherapy, PT001 (GP MDI) to Spiriva. Both PT003 and PT001 products are based on Pearl's novel cosuspension formulation platform for metered dose inhalers. These data are being presented at the 2011 European Respiratory Society (ERS) annual meeting, which is being held in Amsterdam.

"It has recently been shown that the progressive reduction of resting IC is associated with the development of an increasingly shallow, rapid breathing pattern and worsening shortness of breath during exercise," explained Colin Reisner, Pearl's chief medical officer and executive vice president of clinical development. "Improvement in IC correlates well with improvement in dyspnea at rest and with exercise, as well as overall exercise endurance. PT003 provided substantial improvement in IC relative to Spiriva after the initial dose, with further improvements following chronic dosing. These data suggest that PT003 may provide significant improvements in symptomatic benefits and exercise performance and supports further evaluation." '/>"/>

SOURCE Pearl Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI
2. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
3. Pearl Therapeutics Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
4. Asante Solutions Receives FDA Clearance for Pearl™ Insulin Pump
5. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
6. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
7. Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump
8. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
9. Afraxis Enters Collaboration with NIH as Part of Therapeutics for Rare and Neglected Disease Program
10. Reed V. Tuckson, M.D., Executive Vice President and Chief of Medical Affairs at UnitedHealth Group, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
11. Prime Therapeutics Launches CareCentered Contracting™ Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014  Medical Diagnostic Laboratories, L.L.C., (MDL), ... high complexity, state-of-the-art, automated DNA-based molecular analyses, ... Cystic Fibrosis Testing which utilizes cutting edge ... Cystic fibrosis (CF), or mucoviscidosis, ... affects the respiratory, gastrointestinal and reproductive systems. ...
(Date:10/22/2014)... Oct. 22, 2014  Rescheduling of hydrocodone combination ... the pain market, according to a new primary ... firm providing market research and consultation exclusively in ... - http://photos.prnewswire.com/prnh/20141021/153440 In ... hydrocodone combination products from Schedule III to Schedule ...
(Date:10/22/2014)... -- Investor-Edge has initiated coverage on the ... ), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX ), ... Pharmaceuticals Inc. (NASDAQ: IDRA ), and Merrimack ... companies can be accessed at: http://investor-edge.com/register . ... ended at 4,419.48, up 2.40%, the Dow Jones Industrial ...
Breaking Medicine Technology:Medical Diagnostic Laboratories, L.L.C. Institute for Biomarker Research Announces New Prenatal Cystic Fibrosis Tests 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5
(Date:10/25/2014)... 2014 TASC (Total Administrative Services ... benefits account management services, announces the release of ... on taxes, reduce administrative workload, and lessen liability. ... and the efficient handling of complex, time-sensitive, and ... best meets their goals and objectives. The four ...
(Date:10/25/2014)... 2014 The federal judge overseeing ... ) filed against Boston Scientific Corp. in the ... Southern District of West Virginia has denied a ... in a group of cases filed on behalf ... October 21st, U.S. District Judge Joseph R. Goodwin ...
(Date:10/25/2014)... (HealthDay News) -- Not getting the right amount of ... new study suggests. Those who sleep less or ... night may be more prone to developing the chronic ... The study authors concluded that duration and quality of ... with inflammatory bowel diseases. "Both short and long ...
(Date:10/25/2014)... 24, 2014 (HealthDay News) -- October,s shorter, darker days ... affective disorder, according to an expert. People ... feel overly tired, lack motivation and even have trouble ... lead to suicide, said Dr. Angelos Halaris, a professor ... Loyola University Chicago Stitch School of Medicine. "Seasonal ...
(Date:10/22/2014)... Isabel Healthcare will participate ... (ASAHP) Conference on October 22-24 in Las Vegas, NV. ... a panel discussion on Technology in Health Professions Education ... a diagnostic decision support tool and clinical education platform ... students and clinical learners. The Isabel tools help clinicians ...
Breaking Medicine News(10 mins):Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2
... ... ... Dozier Internet Law, P.C. has filed a lawsuit (Case No. CGC-10-499227) on behalf of ... San Francisco, against Yelp! Inc. The lawsuit alleges that Yelp! has been operating an ...
... Abstract 35P: Markers for risk of pregnancy-associated breast ... child-birth to the third and fourth decades, the ... rise. This paper suggests that identification of p53 ... outbreak or early detection of pregnancy-associated breast cancer. ...
... as epigenetic modifications, regulate the activity of many ... often inactivates important cellular growth brakes. Therefore, this ... major cause of uncontrolled division of cancer cells. ... methylation. Unlike changes in the blueprint ...
... one wants antibiotic residues in their milk. But antibiotics are ... conducted nowadays take hours to produce a result and do ... can now be closed, thanks to a fully automated minilab ... LMU Muenchen and gwk Praezisionstechnik GmbH. Even at ...
... had previous sprain, study says , FRIDAY, May 7 ... in female high school volleyball players, a new study ... players (59.3 percent female, 40.7 percent male) who wore ... and non-rigid) for an entire season and 42 who ...
... contraceptives altered the social and sexual landscape in ways expected ... millions of women have taken it at some point in ... have been arrested for it and it,s still one of ... it,s simply known as "the Pill." , On May 9, ...
Cached Medicine News:Health News:Yelp! Sued Over Alleged Protection Racket 2Health News:Interesting stories at the IMPAKT Breast Cancer Conference 2Health News:Interesting stories at the IMPAKT Breast Cancer Conference 3Health News:Fatty acid to enhance anticancer drug 2Health News:Minilab can quickly identify antibiotic residues in milk, before it leaves the barn 2Health News:Minilab can quickly identify antibiotic residues in milk, before it leaves the barn 3Health News:Ankle Braces May Protect Girl Volleyball Players 2Health News:The Pill Turns 50 2Health News:The Pill Turns 50 3Health News:The Pill Turns 50 4Health News:The Pill Turns 50 5
... Ureteral Stents have all the advantages ... addition, a unique 360 degree kidney ... placement in the renal pelvis or ... remarkably comfortable stent, ideal for use ...
All the advantages of Dr. Roy P. Finney's classic stent design with an open tip....
This EIA microplate opens new perspectives in the direct detection of Chlamydia. The choice of microplate immunoenzymatic technology and the use of a monoclonal antibody result in a combination of c...
Inquire...
Medicine Products: